Hsbc Holdings PLC Grows Position in Amedisys, Inc. (NASDAQ:AMED)

Hsbc Holdings PLC grew its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 72.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 2,519 shares of the health services provider’s stock after buying an additional 1,060 shares during the period. Hsbc Holdings PLC’s holdings in Amedisys were worth $731,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of AMED. Thornburg Investment Management Inc. purchased a new stake in Amedisys during the fourth quarter worth $27,907,000. BlackRock Inc. raised its position in shares of Amedisys by 2.4% in the fourth quarter. BlackRock Inc. now owns 3,980,184 shares of the health services provider’s stock worth $1,167,506,000 after acquiring an additional 92,634 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Amedisys by 7.8% during the 4th quarter. JPMorgan Chase & Co. now owns 1,137,542 shares of the health services provider’s stock worth $333,675,000 after acquiring an additional 82,251 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Amedisys by 13.1% during the 4th quarter. Alliancebernstein L.P. now owns 462,477 shares of the health services provider’s stock valued at $135,658,000 after acquiring an additional 53,555 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Amedisys by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,560,457 shares of the health services provider’s stock valued at $457,729,000 after purchasing an additional 52,343 shares in the last quarter. 85.87% of the stock is owned by hedge funds and other institutional investors.

AMED has been the topic of several research analyst reports. Benchmark raised their price objective on Amedisys from $275.00 to $325.00 and gave the company a “buy” rating in a report on Monday, March 1st. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Amedisys from $275.00 to $340.00 and gave the company a “buy” rating in a research note on Monday, February 8th. They noted that the move was a valuation call. Finally, Truist increased their price objective on shares of Amedisys from $280.00 to $325.00 in a report on Tuesday, January 5th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $268.64.

In other Amedisys news, insider Denise M. Bohnert sold 526 shares of the stock in a transaction that occurred on Wednesday, January 20th. The shares were sold at an average price of $300.84, for a total transaction of $158,241.84. Following the sale, the insider now directly owns 9,259 shares in the company, valued at approximately $2,785,477.56. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Scott G. Ginn sold 975 shares of the business’s stock in a transaction on Friday, January 29th. The stock was sold at an average price of $286.87, for a total transaction of $279,698.25. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,408 shares of company stock worth $1,227,928. Company insiders own 2.80% of the company’s stock.

Shares of NASDAQ:AMED opened at $267.73 on Thursday. The company has a market capitalization of $8.79 billion, a price-to-earnings ratio of 53.65, a PEG ratio of 3.18 and a beta of 0.77. Amedisys, Inc. has a 12-month low of $165.42 and a 12-month high of $325.12. The business has a 50-day moving average price of $267.01 and a 200 day moving average price of $267.99. The company has a current ratio of 0.94, a quick ratio of 0.94 and a debt-to-equity ratio of 0.40.

Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, February 23rd. The health services provider reported $1.49 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.47 by $0.02. The company had revenue of $550.71 million during the quarter, compared to analyst estimates of $551.91 million. Amedisys had a net margin of 8.22% and a return on equity of 26.41%. During the same quarter last year, the firm posted $0.94 earnings per share. As a group, equities research analysts predict that Amedisys, Inc. will post 6.07 earnings per share for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

See Also: What are benefits of a growth and income fund?

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.